UBS Group’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q4
– Sell
-4,900
Closed -$104K – 9676
2014
Q3
$104K Buy
4,900
+4,800
+4,800% +$78.4K ﹤0.01% 5942
2014
Q2
$1K Buy
+100
New +$1.42K ﹤0.01% 10179

Other funds holding ABUS

UBS Group's ABUS Position: Q3 2026 in Review

UBS Group reduced its Arbutus Biopharma (ABUS) stake by 16% in Q3 2026, selling an estimated $187K and leaving 210,370 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #5653.

UBS Group first reported a position in ABUS in Q3 2013 and has held it in 49 quarters since. The position peaked at $3.52M in Q3 2025. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • UBS Group held 210,370 shares of Arbutus Biopharma worth $1.01M as of Q3 2026.
  • UBS Group sold 38,838 Arbutus Biopharma shares in Q3 2026, an estimated $187K.
  • Arbutus Biopharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5653 holding.
  • UBS Group first reported a position in Arbutus Biopharma in Q3 2013 and has held it in 49 quarters since.
  • UBS Group's Arbutus Biopharma position peaked at $3.52M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.